The Global Peptide
Therapeutics Landscape
40+ Publicly Traded Companies Across Three Core Categories: Therapeutic Developers • Manufacturing Services • Research Tools
Market Snapshot
Executive Summary
The global peptide therapeutics landscape encompasses 40+ publicly traded companies across major exchanges, spanning three core categories: therapeutic developers (from clinical-stage to commercial giants like Novo Nordisk and Eli Lilly), manufacturing/service providers (CDMOs like Bachem, PolyPeptide, and emerging TAIDE Pharmaceutical), and research/diagnostic tool companies.
For retail peptide access, Hims & Hers Health (HIMS) stands out with its 2025 peptide facility acquisition and telehealth integration, while The Precision Peptide Company (PNGA.F) offers consumer-facing peptide products. Most peptide therapeutics remain prescription-based, but telehealth platforms and wellness-oriented companies are creating new consumer access pathways.
United States Markets
NASDAQ-Listed Therapeutics Developers
Protagonist Therapeutics, Inc. (PTGX)
Clinical-stage biopharmaceutical company
Founded in 2006 and IPO on August 11, 2016, Protagonist Therapeutics has established itself as a pioneer in peptide-based drug development. The company's therapeutic portfolio spans inflammatory, hematologic, and metabolic diseases.
Entera Bio Ltd. (ENTX)
Oral peptide delivery specialist
Entera Bio exclusively focuses on orally delivered peptide therapies, addressing one of the most persistent challenges in this drug class. Their proprietary oral delivery technology platform enables systemic absorption through the gastrointestinal tract.
Osteoporosis (Phase 2/3)
Crohn's disease (Phase 2)
Hypoparathyroidism
Hims & Hers Health, Inc. (HIMS)
Telehealth + Peptide Manufacturing
Hims & Hers Health represents the most significant publicly traded company positioned to offer peptide solutions directly to retail consumers. In February 2025, the company acquired a U.S.-based peptide manufacturing facility in California, creating vertical integration from manufacturing through direct-to-consumer distribution.
- Vertical integration
- Telehealth platform
- Direct-to-consumer model
- Product diversification
- Preventive health
- Metabolic optimization
- Cognitive performance
- Recovery science
European Markets
Swiss CDMO Leaders
Bachem Holding AG (BANB)
Global leader in peptide synthesis
Founded in 1971, Bachem Holding AG stands as the undisputed global leader in peptide synthesis, commanding a dominant position in the CDMO market. With over 500 biopharmaceutical clients worldwide and major facilities in Switzerland, California, and Oregon.
Zealand Pharma A/S (ZEAL)
Pure-play peptide therapeutics
Zealand Pharma A/S represents one of the most successful pure-play peptide therapeutics companies globally. Founded in 1998 and headquartered in Copenhagen, the company discovered and developed lixisenatide, licensed to Sanofi for type 2 diabetes treatment.
Asia-Pacific Markets
TAIDE Pharmaceutical / MEDTIDE INC. (03880)
Emerging global peptide CRDMO
TAIDE Pharmaceutical represents a significant emerging force in the global peptide CRDMO landscape. Their Hong Kong Stock Exchange IPO was oversubscribed by 301.15 times, demonstrating exceptional investor demand.
PeptiDream Inc. (4587)
Peptide discovery platform leader
PeptiDream Inc. stands as one of the most technologically sophisticated peptide-focused biotechnology companies globally. Their proprietary Peptide Discovery Platform System (PDPS) enables production of highly diverse, non-standard peptide libraries.
Oncology
Multiple myeloma
COVID-19
Acromegaly
Business Model Categories
Major Market Categories
Therapeutic Developers
From clinical-stage to commercial giants like Novo Nordisk and Eli Lilly
Manufacturing Services
CDMOs like Bachem, PolyPeptide, and emerging TAIDE Pharmaceutical
Research Tools
Diagnostic peptides and research-grade synthesis services
Consumer-Facing Solutions
Direct-to-Consumer Health
Telehealth + Manufacturing Integration
- • Prescription through licensed providers
- • Future direct peptide products
- • Preventive health applications
- • Metabolic optimization
Cosmetic & Wellness
Plant-based foods + Therapeutic peptides
- • Consumer products
- • Private label formulations
- • Stress management
- • Skin & hair health
Investment Considerations
Large-Cap
Mid-Cap
Small/Micro-Cap
Future Trends & Retail Access
Telehealth Integration Impact
Traditional Model Challenges
- • In-person physician visits required
- • Pharmacy fulfillment delays
- • Insurance processing friction
- • Generic product limitations
- • Reactive treatment approach
Telehealth-Integrated Benefits
- • Digital consultation convenience
- • Direct shipment speed
- • Transparent pricing
- • Personalized formulations
- • Proactive health optimization
GLP-1 Market Expansion
Market Analysis & Key Insights
Market Leaders
Emerging Players
Key Investment Takeaways
- 40+ publicly traded companies globally, spanning therapeutic developers, manufacturing services, research tools, and emerging consumer-facing platforms
- Direct retail access remains limited with Hims & Hers Health (HIMS) representing the most significant opportunity through telehealth integration
- GLP-1 metabolic disease franchise has validated enormous commercial potential, driving unprecedented investment in manufacturing capacity
- Manufacturing and service providers offer lower-risk exposure to sector growth with established market positions
- Micro-cap companies provide speculative exposure but require careful due diligence given substantial developmental risks